Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-019 heterologous booster study in healthy Japanese adults
jRCT2071210141Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Takeda. Primary endpoints: GMT ratio of neutralizing antibody titers to ancestral strain on Day 15 versus Day 36 in TAK-019-1501, Solicited local adverse events after first booster and 7 more. Started Apr 2022; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071210141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210141.